Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMSJVAM)

Drug Name
Amisulpride Drug Info
Synonyms
Aminosultopride; Amisulpiride; Amisulprida; Amisulpridum; Deniban; Socian; Solian; Amisulpride [INN]; DAN 2163; Amisulprida [INN-Spanish]; Amisulpride (INN); Amisulpridum [INN-Latin]; DAN-2163; Deniban (TN); Solian (TN); Solian, Amisulpride; SL-91.1077; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-anisamid; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide; 4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide
Therapeutic ClassAntipsychotic Agents
Cross-matching ID
PubChem CID
2159
ChEBI ID
CHEMBL243712
CAS Number
CAS 71675-85-9
TTD Drug ID
D03ELL
VARIDT Drug ID
DR01259
ACDINA Drug ID
D00835

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Spliceosome 2.64 0.00e+0 101/150 (67.33%) HNRNPM;FUS;SRSF6;...
DNA replication 2.61 0.00e+0 34/36 (94.44%) MCM3;MCM5;MCM4;...
Cell cycle 2.60 0.00e+0 110/124 (88.71%) CDC20;CCNA2;PLK1;...
Progesterone-mediated oocyte maturation 2.21 0.00e+0 75/100 (75%) CCNA2;PLK1;AURKA;...
RNA transport 2.17 0.00e+0 128/186 (68.82%) EIF1AY;FUS;TACC3;...
Pyrimidine metabolism 2.10 0.00e+0 40/56 (71.43%) TYMS;RRM2;CTPS1;...
Fanconi anemia pathway 2.04 6.90e-4 36/54 (66.67%) USP1;BRCA1;FANCI;...
Ribosome biogenesis in eukaryotes 2.01 6.03e-4 52/108 (48.15%) HEATR1;NHP2;RPP40;...
Homologous recombination 1.96 1.61e-3 35/41 (85.37%) BRCA1;RAD54B;TOPBP1;...
Mismatch repair 1.87 2.90e-3 22/23 (95.65%) RFC3;EXO1;LIG1;...
RNA degradation 1.87 2.63e-3 53/79 (67.09%) EXOSC9;LSM6;LSM5;...
One carbon pool by folate 1.84 2.41e-3 15/20 (75%) TYMS;DHFR;MTR;...
Oocyte meiosis 1.83 2.97e-3 90/129 (69.77%) CDC20;PLK1;AURKA;...
Non-homologous end-joining 1.77 6.21e-3 11/13 (84.62%) PRKDC;DCLRE1C;FEN1;...
Aminoacyl-tRNA biosynthesis 1.68 1.48e-2 15/66 (22.73%) SARS2;FARSA;DARS2;...
Nucleotide excision repair 1.66 1.75e-2 40/47 (85.11%) RFC3;POLE2;LIG1;...
Base excision repair 1.66 1.68e-2 29/33 (87.88%) POLE2;FEN1;LIG1;...
Ribosome 1.63 2.04e-2 113/158 (71.52%) RPS4Y1;MRPS12;MRPL12;...
Ubiquitin mediated proteolysis 1.54 4.88e-2 87/140 (62.14%) CDC20;BRCA1;SMURF2;...
Fluid shear stress and atherosclerosis -1.74 2.27e-2 123/139 (88.49%) ACVR1;GSTA1;ACVR2B;...
Neutrophil extracellular trap formation -1.74 2.30e-2 101/189 (53.44%) ATG7;ITGB3;TLR2;...
Chemokine signaling pathway -1.76 2.12e-2 163/192 (84.9%) JAK2;BRAF;CXCR2;...
Collecting duct acid secretion -1.76 2.10e-2 22/27 (81.48%) TCIRG1;ATP6V1F;ATP6V0E2;...
Complement and coagulation cascades -1.77 1.97e-2 76/85 (89.41%) CFD;PLAUR;C2;...
Mitophagy -1.77 1.94e-2 56/68 (82.35%) ULK1;TFE3;NBR1;...
Graft-versus-host disease -1.78 1.91e-2 32/42 (76.19%) HLA-F;TNF;IL6;...
Glycerolipid metabolism -1.79 1.59e-2 44/61 (72.13%) ALDH2;DGKI;PLPP1;...
Other glycan degradation -1.79 1.53e-2 13/18 (72.22%) AGA;HEXA;MANBA;...
Ether lipid metabolism -1.80 1.61e-2 32/49 (65.31%) LPCAT1;CHPT1;PLA2G4C;...
Notch signaling pathway -1.80 1.69e-2 49/59 (83.05%) PSEN2;NOTCH4;NOTCH1;...
Rheumatoid arthritis -1.81 1.78e-2 78/93 (83.87%) TCIRG1;ATP6V1F;ATP6V0E2;...
Renin-angiotensin system -1.82 1.58e-2 20/23 (86.96%) CTSG;KLK1;PRCP;...
Terpenoid backbone biosynthesis -1.83 1.35e-2 18/22 (81.82%) GGPS1;MVD;FNTA;...
Mineral absorption -1.87 9.28e-3 48/60 (80%) TRPV6;HEPH;ATP1B1;...
Allograft rejection -1.87 9.90e-3 32/38 (84.21%) CD80;IL10;FAS;...
Glycosaminoglycan degradation -1.87 7.72e-3 19/19 (100%) GUSB;NAGLU;HEXA;...
TNF signaling pathway -1.88 8.31e-3 103/112 (91.96%) CASP8;IL18R1;CREB3L2;...
Antigen processing and presentation -1.88 9.00e-3 60/78 (76.92%) HLA-F;TNF;TAP1;...
PPAR signaling pathway -1.92 4.91e-3 66/74 (89.19%) ACOX1;FABP6;SLC27A2;...
Cytokine-cytokine receptor interaction -1.94 2.70e-3 246/295 (83.39%) GDF9;CLCF1;FAS;...
Staphylococcus aureus infection -2.01 0.00e+0 72/95 (75.79%) KRT31;DEFA6;DEFA5;...
Hematopoietic cell lineage -2.05 0.00e+0 90/99 (90.91%) CSF2RA;IL4R;ITGAM;...
Steroid biosynthesis -2.09 0.00e+0 19/20 (95%) DHCR24;HSD17B7;LSS;...
Asthma -2.10 0.00e+0 25/31 (80.65%) EPX;HLA-DQB1;TNF;...
Sphingolipid metabolism -2.15 0.00e+0 32/49 (65.31%) SGMS1;PLPP1;PLPP2;...
Viral protein interaction with cytokine and cytokine re... -2.19 0.00e+0 84/100 (84%) PF4;CCL18;IL18RAP;...
Phagosome -2.21 0.00e+0 118/152 (77.63%) COLEC12;ATP6V0B;DYNC1LI1;...
Lysosome -2.27 0.00e+0 115/128 (89.84%) LAPTM4A;CLTA;CTSG;...
Ferroptosis -2.39 0.00e+0 36/41 (87.8%) ACSL5;NCOA4;ACSL1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H, 24H